Kovack Advisors’s Nektar Therapeutics NKTR Stock Holding History

Kovack Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-211	Closed	-$336K	–	501
2018 Q1	$336K	Sell	211 -54	-20%	-$69.6K	0.08%	281
2017 Q4	$237K	Buy	+265	New	+$157K	0.06%	361

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kovack Advisors's NKTR Position: Q2 2018 in Review

Kovack Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 211 shares — an estimated $336K sold.

Kovack Advisors first reported a position in NKTR in Q4 2017 and held it in 2 quarters. The position peaked at $336K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

Kovack Advisors reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
Kovack Advisors sold 211 Nektar Therapeutics shares in Q2 2018, an estimated $336K.
Kovack Advisors first reported a position in Nektar Therapeutics in Q4 2017 and held it in 2 quarters.
Kovack Advisors's Nektar Therapeutics position peaked at $336K in Q1 2018.
379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Kovack Advisors's 13F filing for Q2 2018, filed 1 Aug 2018.